Product Description
BHV-1400 is a potential first-in-class Gd-IgA1 TRAP degrader, rationally designed to leverage the body's natural hepatic clearance mechanisms to selectively target and remove Gd-IgA1, the underlying cause of the IgA nephropathy and IgA vasculitis. BHV-1400 spares IgG, IgA, IgE, and IgM to preserve patient immune protection against bacteria, viruses and parasites. The results of the ongoing Phase 1 study confirm that BHV-1400 produces deep reductions in Gd-IgA1 within hours, is selective, sparing other immunoglobulins, is tunable, and is safe and well-tolerated. (Sourced from: https://ir.biohaven.com/news-releases/news-release-details/biohaven-highlights-innovation-and-advancement-across-mode-and)
Mechanisms of Action: TRAP Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Biohaven Therapeutics Ltd.
Company Location: Eastern America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United Kingdom, United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Biohaven presented P1 IgA Nephropathy results on 2026-05-27 for BHV-1400
- Clinical Trial Start Expected - Biohaven announced they will initiate a P3 IgA Nephropathy trial in 3Q26 for BHV-1400
- Clinical Outcomes Expected - Biohaven announced they will present P3 IgA Nephropathy results in 3Q26 for BHV-1400
Highest Development Phases
Phase 3: Glomerulonephritis|IgA Nephropathy|Kidney Failure, Chronic|Proteinuria
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07054684 |
BHV1400-102 | P1 |
Recruiting |
Glomerulonephritis|IgA Nephropathy|Proteinuria|Kidney Failure, Chronic |
2027-07-01 |
50% |
2026-02-18 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT07642050 |
BHV1400-301 | P3 |
Not yet recruiting |
Kidney Failure, Chronic|Proteinuria|Glomerulonephritis|IgA Nephropathy |
2028-09-01 |
31% |
2026-06-12 |
Primary Endpoints|Treatments |